CompletedPHASE1, PHASE2NCT01033552
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Studying Inherited epidermolysis bullosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Principal Investigator
- Jakub Tolar, MD, PhDMasonic Cancer Center, University of Minnesota
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 32 target
- Eligibility
- 25 years · All sexes
- Timeline
- 2010 – 2021
Study locations (1)
- University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01033552 on ClinicalTrials.govOther trials for Inherited epidermolysis bullosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05838092Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGPHASE3NCT05464381Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGNANCT05248503Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05954416FARD (RaDiCo Cohort) (RaDiCo-FARD)Institut National de la Santé Et de la Recherche Médicale, France